Medtronic Receives Hold Rating from Wolfe Research
ByAinvest
Monday, Aug 25, 2025 10:46 am ET1min read
MDT--
Key highlights include:
- Cardiac Ablation Solutions revenue increased nearly 50%, driven by a 72% increase in the U.S. market, largely due to the strength of pulsed field ablation (PFA) products [1].
- The U.S. Centers for Medicare & Medicaid Services (CMS) proposed a National Coverage Determination (NCD) for the Symplicity Spyral system for hypertension, with a final NCD expected by October 8, 2025 [1].
- Medtronic received CE Mark approval for LigaSure™ RAS vessel-sealing technology on the Hugo™ robotic-assisted surgery (RAS) system [1].
Medtronic's Q1 GAAP operating profit and operating margin were $1.445 billion and 16.8%, respectively, up 13% and 70 basis points year-over-year [1]. Non-GAAP operating profit and operating margin were $2.016 billion and 23.6%, respectively, up 3% and down 80 basis points [1].
The company raised its FY26 EPS guidance to the range of $5.60 to $5.66 per share, from the prior range of $5.50 to $5.60, and expects FY26 organic revenue growth of approximately 5% [1]. This increase is attributed to unexpectedly strong Q1 results and a lessened impact of tariffs.
Wolfe Research analyst Michael Polark reiterated a Hold rating on Medtronic, citing the company's latest earnings release [2]. Polark has a 4-star rating and a 51.81% success rate, according to TipRanks [2].
References:
[1] https://www.todaysmedicaldevelopments.com/news/medtronic-reports-first-quarter-fiscal-2026-financial-results/
[2] https://www.ainvest.com/news/medtronic-reports-q1-2025-earnings-sales-reach-8-578bn-net-income-1-04bn-2508/
Wolfe Research analyst Michael Polark reiterated a Hold rating on Medtronic, citing the company's latest earnings release for the quarter ending July 25, which reported a quarterly revenue of $8.58 billion and a net profit of $1.04 billion. Polark has a 4-star rating and a 51.81% success rate, according to TipRanks.
Medtronic plc (MDT) reported robust financial results for its first quarter (Q1) of fiscal year 2026 (FY26), ending July 25, 2025. The company reported revenue of $8.578 billion, a 8.4% increase as reported and 4.8% organic growth, compared to the same period last year [1]. The adjusted revenue was $8.539 billion, with organic revenue growth of 4.8% [1].Key highlights include:
- Cardiac Ablation Solutions revenue increased nearly 50%, driven by a 72% increase in the U.S. market, largely due to the strength of pulsed field ablation (PFA) products [1].
- The U.S. Centers for Medicare & Medicaid Services (CMS) proposed a National Coverage Determination (NCD) for the Symplicity Spyral system for hypertension, with a final NCD expected by October 8, 2025 [1].
- Medtronic received CE Mark approval for LigaSure™ RAS vessel-sealing technology on the Hugo™ robotic-assisted surgery (RAS) system [1].
Medtronic's Q1 GAAP operating profit and operating margin were $1.445 billion and 16.8%, respectively, up 13% and 70 basis points year-over-year [1]. Non-GAAP operating profit and operating margin were $2.016 billion and 23.6%, respectively, up 3% and down 80 basis points [1].
The company raised its FY26 EPS guidance to the range of $5.60 to $5.66 per share, from the prior range of $5.50 to $5.60, and expects FY26 organic revenue growth of approximately 5% [1]. This increase is attributed to unexpectedly strong Q1 results and a lessened impact of tariffs.
Wolfe Research analyst Michael Polark reiterated a Hold rating on Medtronic, citing the company's latest earnings release [2]. Polark has a 4-star rating and a 51.81% success rate, according to TipRanks [2].
References:
[1] https://www.todaysmedicaldevelopments.com/news/medtronic-reports-first-quarter-fiscal-2026-financial-results/
[2] https://www.ainvest.com/news/medtronic-reports-q1-2025-earnings-sales-reach-8-578bn-net-income-1-04bn-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet